oxaprozin (BioDeep_00000398445)

Main id: BioDeep_00000002736

 


代谢物信息卡片


oxaprozin

化学式: C18H15NO3 (293.1052)
中文名称: 奥沙普秦
谱图信息: 最多检出来源 Mus musculus(urine) 16.23%

分子结构信息

SMILES: C1=CC=C(C=C1)C2=C(OC(=N2)CCC(=O)O)C3=CC=CC=C3
InChI: InChI=1S/C18H15NO3/c20-16(21)12-11-15-19-17(13-7-3-1-4-8-13)18(22-15)14-9-5-2-6-10-14/h1-10H,11-12H2,(H,20,21)

描述信息

M - Musculo-skeletal system > M01 - Antiinflammatory and antirheumatic products > M01A - Antiinflammatory and antirheumatic products, non-steroids > M01AE - Propionic acid derivatives
D018501 - Antirheumatic Agents > D000894 - Anti-Inflammatory Agents, Non-Steroidal > D016861 - Cyclooxygenase Inhibitors
C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic
D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents
D002491 - Central Nervous System Agents > D000700 - Analgesics
C471 - Enzyme Inhibitor > C1323 - Cyclooxygenase Inhibitor
D000893 - Anti-Inflammatory Agents
D004791 - Enzyme Inhibitors
Oxaprozin is an orally active and potent COX inhibitor, with IC50 values of 2.2 μM for human platelet COX-1 and and 36 μM for IL-1-stimulated human synovial cell COX-2, respectively. Oxaprozin also inhibits the activation of NF-κB. Oxaprozin induces cell apoptosis. Oxaprozin shows anti-inflammatory activity. Oxaprozin-mediated inhibition of the Akt/IKK/NF-κB pathway contributes to its anti-inflammatory properties[1][2].

同义名列表

4 个代谢物同义名

oxaprozin; Oxaprozinum; Wy21743; Oxaprozin



数据库引用编号

22 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。

亚细胞结构定位 关联基因列表
Cytoplasm 11 ACE, ALB, ANXA5, CASP3, CYP2C9, NFKB1, PRAME, PTGS1, PTGS2, SIRT1, XIAP
Peripheral membrane protein 3 ANXA5, PTGS1, PTGS2
Endoplasmic reticulum membrane 4 CYP2C9, HMOX1, PTGS1, PTGS2
Nucleus 9 ALB, CASP3, GABPA, HMOX1, NFKB1, PPARGC1A, PRAME, SIRT1, XIAP
cytosol 9 ALB, ANXA5, CASP3, GPT, HMOX1, NFKB1, PPARGC1A, SIRT1, XIAP
centrosome 1 ALB
nucleoplasm 8 CASP3, GABPA, HMOX1, NFKB1, PPARGC1A, PRAME, SIRT1, XIAP
Cell membrane 3 ACE, CD40LG, PRAME
Cytoplasmic side 1 HMOX1
cell surface 2 CD40LG, EPO
glutamatergic synapse 1 CASP3
Golgi apparatus 4 ALB, CD40LG, PRAME, PTGS1
neuronal cell body 1 CASP3
sarcolemma 1 ANXA5
Lysosome 1 ACE
endosome 1 ACE
plasma membrane 5 ACE, CD40LG, CYP2C9, PRAME, REN
Membrane 5 ACE, ANXA5, CD40LG, HMOX1, REN
caveola 1 PTGS2
extracellular exosome 6 ACE, ALB, ANXA5, EPO, GPT, PTGS1
endoplasmic reticulum 3 ALB, HMOX1, PTGS2
extracellular space 7 ACE, ALB, CD40LG, EPO, GNRH1, HMOX1, REN
perinuclear region of cytoplasm 1 HMOX1
mitochondrion 2 NFKB1, SIRT1
protein-containing complex 2 ALB, PTGS2
intracellular membrane-bounded organelle 2 CYP2C9, PTGS1
Microsome membrane 3 CYP2C9, PTGS1, PTGS2
postsynaptic density 1 CASP3
chromatin silencing complex 1 SIRT1
Single-pass type I membrane protein 1 ACE
Secreted 5 ACE, ALB, CD40LG, EPO, REN
extracellular region 7 ACE, ALB, ANXA5, EPO, GNRH1, NFKB1, REN
mitochondrial outer membrane 1 HMOX1
anchoring junction 1 ALB
transcription regulator complex 1 NFKB1
photoreceptor outer segment 1 PTGS1
external side of plasma membrane 3 ACE, ANXA5, CD40LG
nucleolus 1 SIRT1
apical part of cell 1 REN
Single-pass type II membrane protein 1 CD40LG
heterochromatin 1 SIRT1
focal adhesion 1 ANXA5
Nucleus, PML body 2 PPARGC1A, SIRT1
PML body 2 PPARGC1A, SIRT1
collagen-containing extracellular matrix 1 ANXA5
Nucleus inner membrane 1 PTGS2
Nucleus outer membrane 1 PTGS2
nuclear inner membrane 2 PTGS2, SIRT1
nuclear outer membrane 1 PTGS2
Zymogen granule membrane 1 ANXA5
neuron projection 2 PTGS1, PTGS2
ciliary basal body 1 ALB
chromatin 5 GABPA, NFKB1, PPARGC1A, PRAME, SIRT1
Chromosome 1 PRAME
centriole 1 ALB
brush border membrane 1 ACE
spindle pole 1 ALB
blood microparticle 1 ALB
sperm midpiece 1 ACE
Cul2-RING ubiquitin ligase complex 1 PRAME
fibrillar center 1 SIRT1
nuclear envelope 1 SIRT1
Endomembrane system 1 PTGS1
euchromatin 1 SIRT1
cell body 1 EPO
basal plasma membrane 1 ACE
secretory granule lumen 2 EPO, NFKB1
endoplasmic reticulum lumen 2 ALB, PTGS2
platelet alpha granule lumen 1 ALB
specific granule lumen 1 NFKB1
Single-pass type IV membrane protein 1 HMOX1
vesicle membrane 1 ANXA5
[Isoform 1]: Nucleus 1 PPARGC1A
death-inducing signaling complex 1 CASP3
eNoSc complex 1 SIRT1
rDNA heterochromatin 1 SIRT1
endothelial microparticle 1 ANXA5
[Angiotensin-converting enzyme, soluble form]: Secreted 1 ACE
[Isoform Testis-specific]: Cell membrane 1 ACE
[Nuclear factor NF-kappa-B p105 subunit]: Cytoplasm 1 NFKB1
[Nuclear factor NF-kappa-B p50 subunit]: Nucleus 1 NFKB1
I-kappaB/NF-kappaB complex 1 NFKB1
NF-kappaB p50/p65 complex 1 NFKB1
[CD40 ligand, soluble form]: Secreted 1 CD40LG
ciliary transition fiber 1 ALB
[SirtT1 75 kDa fragment]: Cytoplasm 1 SIRT1
[Isoform B4]: Nucleus 1 PPARGC1A
[Isoform B4-8a]: Cytoplasm 1 PPARGC1A
[Isoform B5]: Nucleus 1 PPARGC1A
[Isoform 9]: Nucleus 1 PPARGC1A


文献列表

  • Parisa Khatami, Naser Mirazi, Maryam Khosravi, Maryam Bananej. Nonsteroidal Anti-inflammatory Drug Oxaprozin is Beneficial Against Seizure-induced Memory Impairment in an Experimental Model of Seizures in Rats: Impact On Oxidative Stress and Nrf2/HO-1 Signaling Pathway. Journal of molecular neuroscience : MN. 2022 Apr; 72(4):880-887. doi: 10.1007/s12031-022-01967-2. [PMID: 35084669]
  • Mark J Henderson, Kathleen A Trychta, Shyh-Ming Yang, Susanne Bäck, Adam Yasgar, Emily S Wires, Carina Danchik, Xiaokang Yan, Hideaki Yano, Lei Shi, Kuo-Jen Wu, Amy Q Wang, Dingyin Tao, Gergely Zahoránszky-Kőhalmi, Xin Hu, Xin Xu, David Maloney, Alexey V Zakharov, Ganesha Rai, Fumihiko Urano, Mikko Airavaara, Oksana Gavrilova, Ajit Jadhav, Yun Wang, Anton Simeonov, Brandon K Harvey. A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. Cell reports. 2021 04; 35(4):109040. doi: 10.1016/j.celrep.2021.109040. [PMID: 33910017]
  • Kyung Chan Park, Mahendiran Dharmasivam, Des R Richardson. The Role of Extracellular Proteases in Tumor Progression and the Development of Innovative Metal Ion Chelators that Inhibit their Activity. International journal of molecular sciences. 2020 Sep; 21(18):. doi: 10.3390/ijms21186805. [PMID: 32948029]
  • Kenichi Furihata, Katsuaki Nagasawa, Atsushi Hagino, Yuji Kumagai. A drug-drug interaction study of a novel, selective urate reabsorption inhibitor dotinurad and the non-steroidal anti-inflammatory drug oxaprozin in healthy adult males. Clinical and experimental nephrology. 2020 Mar; 24(Suppl 1):36-43. doi: 10.1007/s10157-020-01855-2. [PMID: 32076889]
  • Filitsa Dimiza, Marialena Lazou, Athanasios N Papadopoulos, Antonios G Hatzidimitriou, George Psomas. Manganese(II) coordination compounds of carboxylate non-steroidal anti-inflammatory drugs. Journal of inorganic biochemistry. 2020 02; 203(?):110906. doi: 10.1016/j.jinorgbio.2019.110906. [PMID: 31707332]
  • Shupeng Liu, Xiang Bao, Songpo Zhang, Heng Zhang, Xiaofeng Lu, Taihao Li, Zhenyi Chen, Na Chen. The study of ultrasound and iontophoresis on oxaprozin transdermal penetration using surface-enhanced Raman spectroscopy. Drug delivery and translational research. 2020 02; 10(1):83-92. doi: 10.1007/s13346-019-00664-9. [PMID: 31407271]
  • Tobie D Lee, Olivia W Lee, Kyle R Brimacombe, Lu Chen, Rajarshi Guha, Sabrina Lusvarghi, Bethilehem G Tebase, Carleen Klumpp-Thomas, Robert W Robey, Suresh V Ambudkar, Min Shen, Michael M Gottesman, Matthew D Hall. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Molecular pharmacology. 2019 11; 96(5):629-640. doi: 10.1124/mol.119.115964. [PMID: 31515284]
  • Marialena Lazou, Antonios G Hatzidimitriou, Athanasios N Papadopoulos, George Psomas. Zinc-oxaprozin compounds: Synthesis, structure and biological activity. Journal of inorganic biochemistry. 2019 06; 195(?):101-110. doi: 10.1016/j.jinorgbio.2019.03.016. [PMID: 30939377]
  • N Mennini, M Cirri, F Maestrelli, P Mura. Comparison of liposomal and NLC (nanostructured lipid carrier) formulations for improving the transdermal delivery of oxaprozin: Effect of cyclodextrin complexation. International journal of pharmaceutics. 2016 Dec; 515(1-2):684-691. doi: 10.1016/j.ijpharm.2016.11.013. [PMID: 27825863]
  • Franca-Maria Klingler, Markus Wolf, Sandra Wittmann, Philip Gribbon, Ewgenij Proschak. Bacterial Expression and HTS Assessment of Soluble Epoxide Hydrolase Phosphatase. Journal of biomolecular screening. 2016 Aug; 21(7):689-94. doi: 10.1177/1087057116637609. [PMID: 27009944]
  • José Lopes-de-Araújo, Ana Rute Neves, Virgínia M Gouveia, Catarina C Moura, Cláudia Nunes, Salette Reis. Oxaprozin-Loaded Lipid Nanoparticles towards Overcoming NSAIDs Side-Effects. Pharmaceutical research. 2016 Feb; 33(2):301-14. doi: 10.1007/s11095-015-1788-x. [PMID: 26350105]
  • Mian Mao, Ling Wang, Xuehua Jiang, Lin Yang. [Determination of oxaprozin in human plasma with high performance liquid chromatography (HPLC) and its application]. Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi. 2013 Jun; 30(3):646-50. doi: NULL. [PMID: 23865335]
  • Sabina Halappanavar, Petra Jackson, Andrew Williams, Keld A Jensen, Karin S Hougaard, Ulla Vogel, Carole L Yauk, Håkan Wallin. Pulmonary response to surface-coated nanotitanium dioxide particles includes induction of acute phase response genes, inflammatory cascades, and changes in microRNAs: a toxicogenomic study. Environmental and molecular mutagenesis. 2011 Jul; 52(6):425-39. doi: 10.1002/em.20639. [PMID: 21259345]
  • Seung Yoon Lee, Jung Kook Suh, Jin Hwa Choi, Woo Jae Jeon, Mi Ae Cheong. Effect of ketorolac and diclofenac on the impairment of endothelium-dependent relaxation induced by reactive oxygen species in rabbit abdominal aorta. Korean journal of anesthesiology. 2010 Sep; 59(3):196-202. doi: 10.4097/kjae.2010.59.3.196. [PMID: 20877705]
  • Munish Ahuja, Avinash S Dhake, Surendra K Sharma, Dipak K Majumdar. Topical ocular delivery of NSAIDs. The AAPS journal. 2008 Jun; 10(2):229-41. doi: 10.1208/s12248-008-9024-9. [PMID: 18437583]
  • Shao-Fa Sun, Bo Zhou, Han-Na Hou, Yi Liu, Guang-Ya Xiang. Studies on the interaction between Oxaprozin-E and bovine serum albumin by spectroscopic methods. International journal of biological macromolecules. 2006 Nov; 39(4-5):197-200. doi: 10.1016/j.ijbiomac.2006.03.020. [PMID: 16828154]
  • Pradip Datta, Deven Scurlock, Amitava Dasgupta. Analytic performance evaluation of a new turbidimetric immunoassay for phenytoin on the ADVIA 1650 analyzer: effect of phenytoin metabolite and analogue. Therapeutic drug monitoring. 2005 Jun; 27(3):305-8. doi: 10.1097/01.ftd.0000164315.13825.dd. [PMID: 15905800]
  • Walter F Kean. Oxaprozin: kinetic and dynamic profile in the treatment of pain. Current medical research and opinion. 2004 Aug; 20(8):1275-7. doi: 10.1185/030079904125004420. [PMID: 15324530]
  • Jeffrey R LaDuca, Peter H Bouman, Anthony A Gaspari. Nonsteroidal antiinflammatory drug-induced pseudoporphyria: a case series. Journal of cutaneous medicine and surgery. 2002 Jul; 6(4):320-6. doi: 10.1007/s10227-001-0051-8. [PMID: 12118363]
  • Y Hu, S Tu, P Liu. A randomized, controlled, single-blind trial of leflunomide in the treatment of rheumatoid arthritis. Journal of Tongji Medical University = Tong ji yi ke da xue xue bao. 2001; 21(1):72-4. doi: 10.1007/bf02888043. [PMID: 11523255]
  • A Marland, P Sarkar, R Leavitt, E Lee-Ruff, J Ramnauth. The elimination profiles of oxaprozin in equine urine and serum after a 4.8-g dose. Journal of analytical toxicology. 1999 Jul; 23(4):242-6. doi: 10.1093/jat/23.4.242. [PMID: 10445486]
  • T Nishikawa, Y Kamijo, H Ohtani, A D Fraser. Oxaprozin interference with urinary benzodiazepine immunoassays and noninterference with receptor assay. Journal of analytical toxicology. 1999 Mar; 23(2):125-6. doi: 10.1093/jat/23.2.125. [PMID: 10192417]
  • S Al-Khenaizan, J F Schechter, D Sasseville. Pseudoporphyria induced by propionic acid derivatives. Journal of cutaneous medicine and surgery. 1999 Jan; 3(3):162-6. doi: 10.1177/120347549900300314. [PMID: 10082597]
  • N M Davies. Clinical pharmacokinetics of oxaprozin. Clinical pharmacokinetics. 1998 Dec; 35(6):425-36. doi: 10.2165/00003088-199835060-00002. [PMID: 9884815]
  • R Rothstein. Safety profiles of leading nonsteroidal anti-inflammatory drugs. The American journal of medicine. 1998 Nov; 105(5A):39S-43S. doi: 10.1016/s0002-9343(98)00280-0. [PMID: 9855175]
  • A D Fraser, P Howell. Oxaprozin cross-reactivity in three commercial immunoassays for benzodiazepines in urine. Journal of analytical toxicology. 1998 Jan; 22(1):50-4. doi: 10.1093/jat/22.1.50. [PMID: 9491969]
  • A Karim, R Noveck, F G McMahon, M Smith, S Crosby, M Adams, J Wilton. Oxaprozin and piroxicam, nonsteroidal antiinflammatory drugs with long half-lives: effect of protein-binding differences on steady-state pharmacokinetics. Journal of clinical pharmacology. 1997 Apr; 37(4):267-78. doi: 10.1002/j.1552-4604.1997.tb04302.x. [PMID: 9115051]
  • G Ingrish, R L Rietschel. Oxaprozin-induced pseudoporphyria. Archives of dermatology. 1996 Dec; 132(12):1519-20. doi: NULL. [PMID: 8961891]
  • A Karim. Inverse nonlinear pharmacokinetics of total and protein unbound drug (oxaprozin): clinical and pharmacokinetic implications. Journal of clinical pharmacology. 1996 Nov; 36(11):985-97. doi: 10.1177/009127009603601102. [PMID: 8973987]
  • M Ogawa, S Ueda, Y Hamano, K Ito, H Saisho, B Akikusa. Membranous nephropathy associated with oxaprozin treatment. Nephron. 1996; 74(2):439-40. doi: 10.1159/000189356. [PMID: 8893177]
  • A F Aubry, N Markoglou, M H Adams, J Longstreth, I W Wainer. The effect of co-administered drugs on oxaprozin binding to human serum albumin. The Journal of pharmacy and pharmacology. 1995 Nov; 47(11):937-44. doi: 10.1111/j.2042-7158.1995.tb03274.x. [PMID: 8708989]
  • M Pulini. False-positive benzodiazepine urine test due to oxaprozin. JAMA. 1995 Jun; 273(24):1905-6. doi: NULL. [PMID: 7783293]
  • T Matuch-Hite, P Jones, J Moriarity. Interference of oxaprozin with benzodiazepines via enzyme immunoassay technique. Journal of analytical toxicology. 1995 Mar; 19(2):130. doi: 10.1093/jat/19.2.130. [PMID: 7769785]
  • P D Camara, L Audette, K Velletri, P Breitenbecher, M Rosner, W C Griffiths. False-positive immunoassay results for urine benzodiazepine in patients receiving oxaprozin (Daypro). Clinical chemistry. 1995 Jan; 41(1):115-6. doi: . [PMID: 7813058]
  • L G Miller. Oxaprozin: a once-daily nonsteroidal anti-inflammatory drug. Clinical pharmacy. 1992 Jul; 11(7):591-603. doi: . [PMID: 1617910]
  • U A Knuth, J Kühne, J Crosby, M Bals-Pratsch, R W Kelly, E Nieschlag. Indomethacin and oxaprozin lower seminal prostaglandin levels but do not influence sperm motion characteristics and serum hormones of young healthy men in a placebo-controlled double-blind trial. Journal of andrology. 1989 Mar; 10(2):108-19. doi: 10.1002/j.1939-4640.1989.tb00071.x. [PMID: 2497096]
  • P R Audet, J A Knowles, S M Troy, B R Walker, G Morrison. Effect of chronic renal failure on oxaprozin multiple-dose pharmacokinetics. Clinical pharmacology and therapeutics. 1988 Sep; 44(3):303-9. doi: 10.1038/clpt.1988.154. [PMID: 3416552]
  • J M Scavone, H R Ochs, D J Greenblatt, R Matlis. Pharmacokinetics of oxaprozin in women receiving conjugated estrogen. European journal of clinical pharmacology. 1988; 35(1):105-8. doi: 10.1007/bf00555518. [PMID: 3220091]
  • T Suwa, H Urano, Y Kohno, A Suzuki, T Amano. Comparative studies on the gastrointestinal lesions caused by several nonsteroidal anti-inflammatory agents in rats. Agents and actions. 1987 Jun; 21(1-2):167-72. doi: 10.1007/bf01974937. [PMID: 3498312]
  • H W Ruelius. Extrapolation from animals to man: predictions, pitfalls and perspectives. Xenobiotica; the fate of foreign compounds in biological systems. 1987 Mar; 17(3):255-65. doi: 10.3109/00498258709043936. [PMID: 3554785]
  • H R Ochs, D J Greenblatt, M Knüchel. Oxaprozin pharmacokinetics in patients with congestive heart failure. Arzneimittel-Forschung. 1986 Dec; 36(12):1837-40. doi: NULL. [PMID: 3566846]
  • S L Bonney, R S Northington, D A Hedrich, B R Walker. Renal safety of two analgesics used over the counter: ibuprofen and aspirin. Clinical pharmacology and therapeutics. 1986 Oct; 40(4):373-7. doi: 10.1038/clpt.1986.193. [PMID: 3530585]
  • J M Scavone, D J Greenblatt, R Matlis, J S Harmatz. Interaction of oxaprozin with acetaminophen, cimetidine, and ranitidine. European journal of clinical pharmacology. 1986; 31(3):371-4. doi: 10.1007/bf00981141. [PMID: 3792438]
  • H W Ruelius, S K Kirkman, E M Young, F W Janssen. Reactions of oxaprozin-1-O-acyl glucuronide in solutions of human plasma and albumin. Advances in experimental medicine and biology. 1986; 197(?):431-41. doi: 10.1007/978-1-4684-5134-4_42. [PMID: 3766273]
  • S Goldfarb, B R Walker, Z S Agus. The uricosuric effect of oxaprozin in humans. Journal of clinical pharmacology. 1985 Mar; 25(2):144-8. doi: 10.1002/j.1552-4604.1985.tb02815.x. [PMID: 3886710]
  • D J Greenblatt, R Matlis, J M Scavone, G T Blyden, J S Harmatz, R I Shader. Oxaprozin pharmacokinetics in the elderly. British journal of clinical pharmacology. 1985 Mar; 19(3):373-8. doi: 10.1111/j.1365-2125.1985.tb02656.x. [PMID: 3986088]
  • S T Chiang, K C Lasseter, E R Fluck, F W Janssen, D Leelavathi, J A Hubsher. Oxaprozin dose proportionality. Journal of clinical pharmacology. 1984 Nov; 24(11-12):515-22. doi: 10.1002/j.1552-4604.1984.tb02761.x. [PMID: 6511991]
  • S T Chiang, J A Knowles, J A Hubsher, H W Ruelius, B R Walker. Effects of food on oxaprozin bioavailability. Journal of clinical pharmacology. 1984 Aug; 24(8-9):381-5. doi: 10.1002/j.1552-4604.1984.tb02790.x. [PMID: 6480879]
  • S Higuchi, Y Osada, Y Shioiri, S Nakaike, M Muramatsu, M Tanaka, I Arai, F Amanuma, S Otomo, H Aihara. [Anti-inflammatory activity of a non-steroidal anti-inflammatory agent, oxaprozin, in experimental models]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica. 1984 May; 83(5):383-94. doi: . [PMID: 6432656]
  • R P Carlson, S C Gilman, T G Hodge, L O'Neill-Davis, E M Blazek, A J Lewis. Effects of oral aspirin and oxaprozin on the development of lupus-like disease in MRL/1 mice. Journal of immunopharmacology. 1984; 6(1-2):69-78. doi: 10.3109/08923978409026459. [PMID: 6432913]
  • S B Kahn, J A Hubsher. Effects of oxaprozin alone or in combination with aspirin on hemostasis and plasma protein binding. Journal of clinical pharmacology. 1983 Apr; 23(4):139-46. doi: 10.1002/j.1552-4604.1983.tb02717.x. [PMID: 6863578]
  • C A Homon, E R Fluck, F W Janssen, H W Ruelius. Protein binding and clearance of oxaprozin, a highly bound anti-inflammatory agent. Agents and actions. 1982 Apr; 12(1-2):211-5. doi: 10.1007/bf01965148. [PMID: 7080958]
  • S T Chiang, G Morrison, J A Knowles, H W Ruelius, B R Walker. Oxaprozin disposition in renal disease. Clinical pharmacology and therapeutics. 1982 Apr; 31(4):509-15. doi: 10.1038/clpt.1982.68. [PMID: 7060332]
  • A Lussier, E LeBel, L Tétreault. Gastrointestinal blood loss of oxaprozin and aspirin with placebo control. Journal of clinical pharmacology. 1982 Apr; 22(4):173-8. doi: 10.1002/j.1552-4604.1982.tb02159.x. [PMID: 6980231]
  • P D Mitnick, A Greenberg, P B DeOreo, B M Weiner, T M Coffman, B R Walker, Z S Agus, S Goldfarb. Effects of two nonsteroidal anti-inflammatory drugs, indomethacin and oxaprozin, on the kidney. Clinical pharmacology and therapeutics. 1980 Nov; 28(5):680-9. doi: 10.1038/clpt.1980.221. [PMID: 7002426]
  • S L McHugh, S K Kirkman, J A Knowles. Macro- and micromethods for high-performance liquid chromatographic analysis of oxaprozin in plasma. Journal of pharmaceutical sciences. 1980 Jul; 69(7):794-6. doi: 10.1002/jps.2600690712. [PMID: 7391941]
  • F W Janssen, W J Jusko, S T Chiang, S K Kirkman, P J Southgate, A J Coleman, H W Ruelius. Metabolism and kinetics of oxaprozin in normal subjects. Clinical pharmacology and therapeutics. 1980 Mar; 27(3):352-62. doi: 10.1038/clpt.1980.47. [PMID: 7357792]
  • T Fukushima. [Monoamine oxidase (XXXVI). Characteristics of benzylamine oxidase in the dog serum]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica. 1975 Jul; 71(5):457-62. doi: . [PMID: 280]